Summary: Insulin, C-peptide and proinsulin were measured in peripheral blood of 11 patients suffering from different types of hormone-producing pancreatic B-cell tumours. While proinsulin was elevated in 10/11 patients during prolonged fasting, C-peptide and insulin levels were found within the reference ränge in 5/ 11 and 3/5 cases respectively. A rapid insulin assay performed during surgery was helpful for localisation and identification of the respective tumours.
Introduction

Materials and Methods
Hypoglycaemia is an ünspecific Symptom of quite Patients with neuroglucopenic Symptoms are subjected to the different diseases, including hormone-producing Bm ™™Z diagnoitic procedure (1): First, a prolonged (5 hours) -~ .' -° \ f oral glucose tolerance test is performed to exclude a reactive cell tumours. Diagnosis of the latter is sometimes hypoglycaemia. The crucial tesl is prolonged fasting, ifpossible, difficult. Blood glucose measurements during pro-over a period of 72 hours. During this time blood glucose is loneed fastin^ caldum infmion and other nro-measured at least every four to six hours. For determination longea lastmg, caicium miusion ana otner pro of ß.^, peptides^ perip heral blood is drawn at the same time, vocative and suppressive tests ars used to confirm but assays are done only tf t h e blood sugar concentrations the diagnosis, but tue existence of an insulinoma is decrease below 500 mg/1. This cut-ofT point is chosen for tvvo substantiated only by elevated serum concentrations ~« firsl : for the patients it avoids the dangei-of severe J J hypoglycaemic attacks; secondly, m our expenence mamof the B-cell peptides insulin, C-peptide and/of pro-tainance of the glucose balance at levels above 500 mg/1 excludes insulin. Here we report our experience in the di-the existence of a hormone-producing B-cell tumour. agnosisof 10 hormone-producing B-cell tumours and Insulin was measured äs described (2) using a guinea pig l case of nesidioblastosis during the last three years. * antiinsulin serurn prepared in our laboratory. C-peptide was dctermined by a commercial assay (Behring-Werke, Marburg), and proinsulin by the procedure described by Heding (3). Sepharose-coupled insulin antibodies cross-reacting with proinsulin were prepared according to 1. c. (3) . The anti-C-peptide serum was the NOVO M 1219 serum, kindly provided by L. Heding. Three different types of human proinsulin Standards were used: first, a pancreatic human proinsulin prepared in 1970 at the University of Chicago (4) and kindly donated by D. Steiner, secondly, human proinsulin material purified in our laboratory from a human insulinoma; thirdly, a new human proinsulin highly purified from b-component at the NOVO Research Institute and kindly provided by V. Kruse. The evaluation data for this latter Standard material were published recently (5) . Identical values were obtained when the new Novo proinsulin Standard was compared with biösynthetic human proinsulin made by recombinant DNA technology (6) . On the basis of these results, the proinsulin values obtained by use of the old "Chicago"-standard äs well äs by use of our own Standard are overestimated by a factor of three. Thus all proinsulin concentrations measured with the old Standard are corrected for this factor.
In some cases B-cell tumoufs are not detectable by other methods such äs coeliacography, abdominal computerized axial tomography and sonography. Although in most of these cases the operating surgeon is able to localize the tumour by palpation, we generally substantiate his finding by insulin measurements in samples obtained during surgery (7) . For this purpose a catheter is inserted into the vena lienalis near the spieen hilus and carefully pushed forward into the vena portae. Localisation of the tumour during surgery An example of the localisation of the tumour by measurements of insulin during surgery is given in figure 2 . The scheme demonstrates the in situ Situation together with the insulin concentrations in plasma samples obtained by catheterization.
Although the operating surgeon (F.S.) had already palpated two tumours, insulin measurements confirmed the presence of two distinct B-cell adenomas.
Results
Figure l demonstrates the diagnostic power of the three B-cell peptides during prolonged fasting of 10 patients suffering from B-cell adenomas or islet cell carcinomas. A single determination of C-peptide and proinsulin in a case of nesidioblastosis is also shown. Insulin was found to be elevated only in 2 out of 5 patients with insulinomas. In 5/11, C-peptide values were within or at the upper level of the reference r nge, while in 6/11 the values were increased 2-5 fold. In 10/11 cases single proinsulin determination confirmed the diagnosis. In these cases proinsulin concentrations were elevated 4-50 fold above the upper level of the reference r nge. In the newborn suffering from nesidioblastosis greatly elevated proinsulin values were found.
Figure l also demonstrates the normalisation of the proinsulin levels in the ser m of one patient (patient 9) after surgery and resection of the insulinoma. From the data shown, an apparent in vivo half-life of proinsulin of about 120 minutes can be calculated, which is higher than reported in the literature (2). 
Discussion
Frequent neuroglucopenic Symptoms usually lead to the diagnostic search for an insulinoma. Although the diagnostic procedures have been greatly improved, it is possible for a patient to suffer for years from a slowly growing tumour before the correct diagnosis is substantiated (8) . The development of radioimmunological methods for the determination of the B-cell peptides, insulin, C-peptide and proinsulin made it possible to measure tissue specific antigens. Pifferences in tissue content, secretion pattern and plasma half-life of these antigens, however, are to be expected, and they do not have the same diagnostic value. The value of insulin measurements is mainly a function of the upper level of the reference r nge employed, which again is dependent on the short half-life of insulin and other influences such s age, sex, body weight etc. The same is true for the corrected insulin/glucose quotient introduced by Turner et al. (9) . Reports in the literature about the diagnostic sensitivity of insulin for the diagnosis of an insulinoma differ accordingly (8) . Before we introduced the C-peptide and proinsulin methods only about 50% of our insulinoma patients were diagnosed immediately from insulin measurements during prolonged fasting. It was hoped that the C-peptide assay would further improve the diagnostic procedure. However in the recent report published by Heding & Kruse (10) on 206 sera from fasting insulinoma patients, elevated C-peptide levels are found in only 50%, which is consistent with the present results. The use of both assays, i. e. insulin and Cpeptide, clearly improves the diagnostic evidence.
Probably due to a reduced storage capacity of the tumour cell (11) and its autonomous secretion, insulinoma patients in general have elevated proinsulin levels in their serum (2, 3, 10 -13). In the above mentioned study (10) only 2/206 sera from insulinoma patients had proinsulin concentrations within the jreference ränge, which is consistent with results reported here on a much smaller group of patients. Thus the diagnostic sensitivity of the proinsulin determination is over 90%. Possibly our one insulinoma patient with normal fasting proinsulin concentrations is similar to the case recently reported by Pichl et al. (14) , in which hormone secretion by an insulinoma showed periodicity. With respect to the diagnostic specificity of the proinsulin determination, further studies are needed. Hyperproinstilinaemia is found in patients with thyrotoxicosis (15) and with cirrhosis (16) .
The observed increase in the plasma half-life of proinsulin in patient 9 might be oaused by the fact that hyperproinsulinaemia in such patients is not only a result of hypersecretion of the autonomous tumour, but is additionally amplified by decreased peripheral degradation (17) . Intraoperatively, about 20 percent of the insulinomas are not detected by inspection or bidigital palpation. Furthermore, in about 12 percent of cases, multiple adenomas are found (18) . Thus tumour localisation either by preoperative transhepatic catherisation (19, 20) or intraoperatively by direct catherisation of the vena lienalis (7, 21) is absolutely necessary. Since the latter method is less dangerous for the patient and the rapid insulin assay needs only about 20 minutes, we prefer the direct catherisation during sürgefy.
